Clinical Pharmacology

7
Pipeline Programs
3
Companies
9
Clinical Trials
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
6
0
0
0
1
0
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

3 companies ranked by most advanced pipeline stage

Takeda
TakedaTOKYO, Japan
1 program
1
SYR-322-METPhase 31 trial
Active Trials
NCT02276274Completed12Est. Jun 2014
Bayer
BayerLEVERKUSEN, Germany
5 programs
5
Fosrenol ODTPhase 11 trial
Loratadine + Pseudoephedrine sulfatePhase 11 trial
Loratadine + Pseudoephedrine sulfatePhase 11 trial
Nifedipine gastrointestinal therapeutic systemPhase 13 trials
RiociguatPhase 11 trial
Active Trials
NCT03074058Completed20Est. Aug 2015
NCT03517930Completed52Est. Jul 2018
NCT03517943Completed29Est. Aug 2018
+4 more trials
Cardurion Pharmaceuticals
1 program
1
CRD-740Phase 11 trial
Active Trials
NCT05437094CompletedEst. Aug 2022

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
TakedaSYR-322-MET
BayerNifedipine gastrointestinal therapeutic system
Cardurion PharmaceuticalsCRD-740
BayerLoratadine + Pseudoephedrine sulfate
BayerLoratadine + Pseudoephedrine sulfate
BayerFosrenol ODT
BayerNifedipine gastrointestinal therapeutic system
BayerRiociguat
BayerNifedipine gastrointestinal therapeutic system

Clinical Trials (9)

Total enrollment: 1,544 patients across 9 trials

Effect of Food on the Pharmacokinetics of Single Oral Dose Administration of a Fixed-Dose Combination of SYR-322 and Metformin Hydrochloride in Healthy Adult Male Subjects

Start: Jun 2014Est. completion: Jun 201412 patients
Phase 3Completed
NCT01788358BayerNifedipine gastrointestinal therapeutic system

Open-Label Long-Term Safety and Efficacy Study of Fixed Dose Combination of Nifedipine Gastrointestinal Therapeutic System and Candesartan Cilexetil in Subjects With Moderate to Severe Essential Hypertension

Start: Feb 2013Est. completion: May 2014508 patients
Phase 3Completed

Effect of Coadministration of Itraconazole on the Pharmacokinetics of CRD-740

Start: Jun 2022Est. completion: Aug 2022
Phase 1Completed
NCT03517943BayerLoratadine + Pseudoephedrine sulfate

A Manufacturing Transfer Study Comparing the Bioequivalence of a Single Oral Dose of Claritin-D 12-Hour Extended Release Tablet From 2 Different Manufactuers Under Fed Conditions in Healthy Adult Subjects

Start: Apr 2018Est. completion: Aug 201829 patients
Phase 1Completed
NCT03517930BayerLoratadine + Pseudoephedrine sulfate

A Manufacturing Transfer Study Comparing the Bioequivalence of a Single Oral Dose of Claritin-D 12-Hour Extended Release Tablet From 2 Different Manufacturers Under Fasted Conditions in Healthy Adult Subjects

Start: Apr 2018Est. completion: Jul 201852 patients
Phase 1Completed
NCT03074058BayerFosrenol ODT

Bioequivalence Study of BAY 77-1931 Orally Disintegrating Tablet

Start: Jun 2015Est. completion: Aug 201520 patients
Phase 1Completed
NCT03136666BayerNifedipine gastrointestinal therapeutic system

Single Dose Escalation Study to Investigate the Pharmacokinetics as Well as Safety and Tolerability of a Concomitant Administration of Nifedipne GITS and Candesartan Tablets Under Fasting Conditions in Healthy Male Subjects in an Open Label, Non-randomized, Sequential Design.

Start: Apr 2010Est. completion: Jun 201012 patients
Phase 1Completed

Study on the Safety of BAY 63-2521, How it is Tolerated and the Way the Body Absorbs, Distributes and Gets Rid of the Study Drug Given as a Single Oral Dose of 1 mg Tablet in Participants With Renal Impairment and Healthy Participants Matched for Age-, Gender-, and Weight

Start: Feb 2010Est. completion: Sep 201140 patients
Phase 1Completed
NCT03194633BayerNifedipine gastrointestinal therapeutic system

Effectiveness and Tolerability of Long-Acting Nifedipine Gastrointestinal Therapeutic System in Chronic Kidney Disease With Uncontrolled Hypertension Patients, a Prospective, Multicenter, Observational Study

Start: Jul 2017Est. completion: Aug 2020871 patients
N/ACompleted

Phase Legend

PreclinicalLab & animal studies
Phase 1Safety & dosing
Phase 2Efficacy testing
Phase 3Large-scale trials
On MarketApproved & available

Key Insights

1 late-stage (Phase 3) programs — potential near-term approvals
3 companies competing in this space